Posted by Michael Wonder on 25 Aug 2021
Avastin biosimilar may bring insurance benefits for Tecentriq
25 August 2021 - The government has been delaying discussing whether to allow reimbursement for Tecentriq (atezolizumab) due to concerns over increased health insurance costs.
However, the arrival of Avastin’s biosimilar may accelerate talks for reimbursement for the combination therapy of Tecentriq and Avastin, industry watchers said.
